AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23519139
Drug: Factor IX
RxNorm normalized name: Factor IX
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor IX Complex (mean dose 35 units/kg)
Trial: 19544758
Drug: Online treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online treatment
Trial: 8217239
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with weekly 5-FU (600 mg/m2)
Trial: 26933811
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (0.04-0.05 mg/kg/day) + donor-derived mesenchymal stem cells (MSCs)
Trial: 26933811
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose tacrolimus (0.07-0.08 mg/kg/day)
Trial: 26933811
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus + MSCs
Trial: 26933811
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose tacrolimus
Trial: 24935932
Drug: DPP4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitor sitagliptin
Trial: 21825083
Drug: VX-809 100
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-809 100 mg
Trial: 21825083
Drug: VX-809 200
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-809 200 mg
Trial: 18523884
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment at 40 degrees C for 2 hours
Trial: 15853214
Drug: YM 294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM 294 (rhlL-11) at a dose of 50 microg/kg
Trial: 15853214
Drug: Non-treatment observation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment observation group
Trial: 8864421
Drug: ANP (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP (10 ng kg‐1 min‐1) during ANG II infusion
Trial: 8864421
Drug: ANP (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANP (10 ng kg‐1 min‐1) during NA infusion
Trial: 1379107
Drug: Finasteride 10
RxNorm normalized name: finasteride 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 10 mg/day
Trial: 7689971
Drug: Finasteride 5
RxNorm normalized name: finasteride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 5 mg/day (3 years therapy)
Trial: 3780288
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam in conventional tablet form on the morning of operation
Trial: 3780288
Drug: Sustained-release diazepam
RxNorm normalized name: diazepam Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release diazepam the night before surgery
Trial: 27287784
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard pharmacotherapy)
Trial: 22699824
Drug: BI 2536
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 2536 200 mg on day 1
Trial: 22699824
Drug: BI 2536
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 2536 60 mg on days 1-3
Trial: 9888075
Drug: Nonpreserved ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpreserved ketorolac tromethamine 0.5% ophthalmic solution, 4 times daily for 3 days or until no ocular pain
Trial: 9438895
Drug: Granisetron 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 1.0 mg
Trial: 27257981
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intraarticular injection of 4 ml lightly cross‐linking sodium hyaluronate (Monovisc)
Trial: 27257981
Drug: Three consecutive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive intraarticular injections of 2.5 ml standard linear sodium hyaluronate (Adant) with one week intervals
Trial: 24366001
Drug: Levobupivacaine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (Group L)
Trial: 23469594
Drug: Mesalazine Enteric-coated
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine Enteric-coated Tablet (MECT)
Trial: 18034666
Drug: Voriconazole 400
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day, followed by 50 mg diclofenac 1 h after the last dose of voriconazole
Trial: 18034666
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase with a single 50-mg oral dose of diclofenac
Trial: 1980733
Drug: Inhaled Magnesium
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Magnesium sulfate (MgS04)
Trial: 1980733
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MgS04 and salbutamol
Trial: 359108
Drug: Butorphanol tartrate
RxNorm normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butorphanol tartrate (mean dose 2.0 mg)
Trial: 359108
Drug: Butorphanol tartrate
RxNorm normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butorphanol tartrate (average 4.6 mg per patient)
Trial: 359108
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate (average 22.8 mg per patient)
Trial: 27986461
Drug: Hourly titrated-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly titrated-dose oral misoprostol solution (20 μg hourly, increased to 40 μg and then to 60 μg)
Trial: 27986461
Drug: 2-hourly static-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hourly static-dose oral misoprostol solution (25 μg every 2 hours)
Trial: 27986461
Drug: Hourly titrated-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hourly titrated-dose oral misoprostol solution
Trial: 27986461
Drug: 2-hourly static-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hourly static-dose oral misoprostol solution
Trial: 23315029
Drug: Olaparib 10
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 10 mg
Trial: 23315029
Drug: Olaparib 30
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 30 mg
Trial: 23315029
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg
Trial: 23315029
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg
Trial: 23315029
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg
Trial: 27422301
Drug: Olaparib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (all doses)
Trial: 17721555
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml bolus doses of 0.1% bupivacaine with butorphanol 2 mg (Group A)
Trial: 17721555
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% plain bupivacaine (Group B)
Trial: 7933501
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anesthesia (TIVA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Trial: 7933501
Drug: Neuroleptanalgesia (NLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptanalgesia (NLA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Trial: 7933501
Drug: Sevoflurane Anesthesia
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane Anesthesia (SA) with vecuronium 0.1 mg.kg‐1 and edrophonium 0.75 mg.kg‐1
Trial: 28120486
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 (25-, 50-, 100-, and 200-mg single dose)
Trial: 23734921
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and interpersonal group therapy
Trial: 18796160
Drug: Pregabalin 600
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 600 mg/d (300 mg BID)
Trial: 17022857
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, titrated to 0.012 mg/kg/day
Trial: 11087880
Drug: Intrathecal methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients)
Trial: 11087880
Drug: Lidocaine alone
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine alone (3 ml of 3 percent lidocaine, 91 patients)
Trial: 11087880
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (90 patients)
Trial: 1582300
Drug: 12 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 micrograms formoterol DP capsules
Trial: 1582300
Drug: 24 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 micrograms formoterol DP capsules
Trial: 1582300
Drug: 48 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 micrograms formoterol DP capsules
Trial: 4075796
Drug: Continuous vitamin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous vitamin supplementation (10 mg vitamin B6 daily or twice the dose daily for 7 non-hormone days)
Trial: 4075796
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive treatment
Trial: 31760846
Drug: Topical cedar
RxNorm normalized name: Cedar oil
DrugBank: Cedar oil (DB10917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cedar solution plus clindamycin 1%
Trial: 31760846
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo plus 1% clindamycin
Trial: 29381544
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of small‐particle hyaluronic acid with lidocaine (SP‐HAL) microaliquots
Trial: 29381544
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection of sterile normal saline
Trial: 29381544
Drug: SP‐HAL treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP‐HAL treatment
Trial: 22117732
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of clinical parameters between turned and TiUnite implants
Trial: 19174782
Drug: Etoricoxib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (60 or 90 mg daily)
Trial: 17701770
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT), mean duration of exposure 8.3 years, 31% exposed for >=10 years
Trial: 17701770
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - route of administration
Trial: 17701770
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) - type of HRT
Trial: 11936169
Drug: Incidental exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incidental exposure to music in daily routine
Trial: 27422026
Drug: Biomarker-guided recommendation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biomarker-guided recommendation on antibiotics (BAL fluid tested for IL-1β and IL-8 in addition to routine microbiology testing)
Trial: 27422026
Drug: Routine use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine use of antibiotics (BAL undergoes routine microbiology testing only)
Trial: 27422026
Drug: Biomarker-guided recommendation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biomarker-guided recommendation on antibiotics
Trial: 25117806
Drug: Pre-filled blister
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled blister packaging labeled for daily use with reminders (MeadWestvaco Corporation's pre-filled DosePak® containing standard doses of statins)
Trial: 21593282
Drug: MS-sNT administered
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-sNT administered with 240 mL of 4% alcohol
Trial: 21593282
Drug: MS-sNT administered
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-sNT administered with 240 mL of 20% alcohol
Trial: 21593282
Drug: MS-sNT administered
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-sNT administered with 240 mL of 40% alcohol
Trial: 21593282
Drug: MS-sNT administered
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MS-sNT administered with water
Trial: 12613392
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prescribed medication and light physical exercises like walking).
Trial: 7651647
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (3.75 or 7.5 mg) in three monthly doses
Trial: 7651647
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (GnRH agonist)
Trial: 2613931
Drug: Adhesive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive antibiotic TA (0.1 mg, 4 applications)
Trial: 361346
Drug: Nefopam (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (90 mg)
Trial: 30255229
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of S-25(OH)D levels (105.3 nmol/L)
Trial: 30255229
Drug: Middle quartiles
RxNorm normalized name: wheat middlings extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle quartiles of S-25(OH)D levels (74.5 nmol/L and 85.7 nmol/L)
Trial: 30255229
Drug: Lowest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest quartile of S-25(OH)D levels (59.3 nmol/L)
Trial: 17674415
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg three times per day, n = 17)
Trial: 9017481
Drug: Saline (2-cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (2-cc vials)
Trial: 8357508
Drug: Oral‐B 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B 40 toothbrush
Trial: 3531313
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg vs Ranitidine
Trial: 24107382
Drug: Difficulties in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Difficulties in instrumental activities of daily living, balance, outdoor mobility
Trial: 20864600
Drug: SNRB+PT (Selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNRB+PT (Selective Nerve Root Block + Physical Therapy)
Trial: 18343300
Drug: Pharmaceutical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatments (specifics not available)
Trial: 27629797
Drug: Psychosocial variables
RxNorm normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial variables (self-efficacy, treatment expectation, social support)
Trial: 23341160
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 30 minutes
Trial: 23341160
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of ß‐lactam antibiotics (meropenem, piperacillin‐tazobactam, cefepime) over 3 hours
Trial: 23341160
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of ß‐lactam antibiotics
Trial: 23341160
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of ß‐lactam antibiotics
Trial: 23341160
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion group
Trial: 23341160
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion group
Trial: 17076053
Drug: High quality
RxNorm normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High quality treatment as usual (control group)
Trial: 9114913
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing (o.d.) of modified-release carbamazepine (CBZ-MR)
Trial: 9114913
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing (b.d.) of modified-release carbamazepine (CBZ-MR)
Trial: 3303997
Drug: Cladosporium allergen
RxNorm normalized name: Cladosporium herbarum allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladosporium allergen preparation
Trial: 31838029
Drug: Oral metolazone
RxNorm normalized name: Metolazone
DrugBank: Metolazone (DB00524)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metolazone
Trial: 21435540
Drug: Implant-anchored treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-anchored treatment (IA group)
Trial: 21435540
Drug: Conventional edgewise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional edgewise treatment (non-IA group)
Trial: 24163282
Drug: Pooled Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pooled Sumatriptan (25 mg and 50 mg)
Trial: 22190398
Drug: rPA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPA vaccine (formalin treated, alum adsorbed, or both)
Trial: 22190398
Drug: rPA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPA vaccine
Trial: 22190398
Drug: AVA (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVA (licensed vaccine)
Trial: 18534975
Drug: Sildenafil (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (0.7 mg/kg body weight, single oral dose)
Trial: 17135987
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fluoxetine and cognitive-behavioral therapy (COMB)
Trial: 11011281
Drug: 0.1% estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% estradiol gel (Gel A)
Trial: 6374193
Drug: Cefaclor (CCL)
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor (CCL) administered 3 times a day at a daily dosage of 750 mg for 3 to 5 days.
Trial: 6374193
Drug: Cephalexin (CEX)
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (CEX) administered 4 times a day at a daily dosage of 1,000 mg for 3 to 5 days.
Trial: 22301087
Drug: Group cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive‐behavioral therapy (CBT) for depression and substance use
Trial: 16108771
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of Peginterferon alpha‐2b + ribavirin (Group A)